OR WAIT 15 SECS
The 60,000-ft2 facility will work in conjunction with the company’s Kakegawa, Japan, clinical supply facility to serve local and global biotech and pharmaceutical companies.
Catalent announced on May 21, 2020 that it will acquire a clinical packaging facility located in Minakuchi, Japan, from Teva-Takeda Pharmaceuticals to further establish its good manufacturing practice manufacturing and distribution hub for clinical studies. Financial details of the acquisition were not disclosed.
The 60,000-ft2 facility will work in conjunction with the company’s Kakegawa, Japan, clinical supply facility to serve local and global biotech and pharmaceutical companies, a Catalent press release said. The new site will provide customers with Catalent’s FastChain demand-led supply services, primary and secondary packaging abilities, temperature options for storage and distribution, and clinical returns and destruction services.
“This new facility provides much-needed capacity as we look to expand our capabilities across the Asia-Pacific region and follows on from recent expansions and investments we have made in our clinical supply business in China and Singapore,” said Ricci Whitlow, president, Catalent Clinical Supply Services, in the press release. “Our strategy has been to build expertise and capacity in this region as demand for local clinical supply services increases, to provide support to customers with global programs, and to meet the growing demand in biologics and cell and gene therapy studies.”